A pharmaceutical physician with 20 years’ experience and knowledge spanning a broad range of disciplines. One of my key strengths is my ability to assimilate new information very quickly, which allows me to easily take on new therapy areas or indications. I am a strategic thinker, providing drug development expertise to the biopharmaceutical industry, focussing on orphan drugs and rare diseases. My current role is focussed on Duchenne muscular dystrophy. Despite having a full-time job, I still try to devote some time to providing pro bono advice to rare disease patient groups on the development of medicines to treat these diseases. I am a member of the Board of Trustees and Scientific Advisory Board for Findacure, a charity for rare diseases (www.findacure.org.uk). I graduated from King’s College London with first class honours in physiology and pharmacology before going on to study medicine at the Royal Free Hospital, London. Specialties: Rare diseases; Orphan Drugs; Clinical Development planning; Medical & regulatory drug development expertise; Company start-up expertise

Therapeutic Area Head Orphan Drugs @ From November 2015 to Present (2 months) London, United KingdomCo-Founder @ Findacure is a charity with the mission to build a movement to promote research and development of treatments for fundamental diseases on behalf of patients and those who care for them. We do this by: ● Empowering patient groups to evolve into effective campaigners for change. ● Facilitating patient groups to drive the development of treatments for fundamental diseases. ● Campaigning for a receptive research environment that recognises the pivotal importance of fundamental diseases. In undertaking our mission, Findacure follows in the footsteps of William Bateson, the father of modern genetics, who reminded us that it is worthwhile to "treasure our exceptions". Fundamental diseases are extreme and rare genetic disorders, which offer a unique opportunity to better understand other diseases, including many common conditions. We have coined this term in order to emphasise the fact that rare diseases are relevant for everyone, not only those people who are affected by them. This paradigm is more relevant today than ever, but has been recognised for centuries, as exemplified by this quote from Dr William Harvey in 1657: “There is no better way to advance the proper practice of medicine than to give our minds to the discovery of the usual law of nature by the careful investigation of cases of rarer forms of disease.” From June 2012 to Present (3 years 7 months) Co-founder & shareholder @ From June 2001 to Present (14 years 7 months) Group Medical Director @ • Recruit and lead a team of medics for the Neuromuscular business; • Accountability for the strategic planning and execution of clinical trial programmes; • Provide clinical expertise for the R&D projects under my care; • Serve as the Medical Monitor for clinical trials; • Collaborate with internal & external stakeholders to ensure successful implementation of projects; • Serve as medical and technical resource for clinical issues raised by internal and external collaborators, investigators, consultants and contract resources; • Participate in the pharmacovigilance process; • Participate in analysis and interpretation of interim and final study data. From July 2015 to October 2015 (4 months) Medical Director Medical Affairs @ I provide medical expertise to the global drug development process and commercial organization with an emphasis on late phase studies. I also provide a strategic lead to the label extension studies for drisapersen and direction and leadership to clinical project managers by acting as Medical Monitor. I work closely with commercial colleagues, providing medical input in preparation for launch and post marketing activities for drisapersen. This includes training of staff, advising on appropriate clinical trial activities, expanded access and registry studies, KOL interactions and visibility on the company booth at scientific meetings. I work closely with the patient advocacy staff, regularly being the company spokesperson at patient group meetings, helping to maintain our relationships with the patient community. From August 2014 to June 2015 (11 months) Principal Consultant @ Cudos is a consultancy company providing advice and guidance on the development of orphan drugs to the biopharmaceutical industry. Assignments range from Chief Medical Officer roles to designing clinical development plans to writing of orphan designation applications. From January 2010 to August 2014 (4 years 8 months) Amsterdam Area, NetherlandsChief Medical Officer @ DCPrime develops dendritic cell-based vaccines for a broad range of cancer types, based on its unique, proprietary technology platform, DCOne™. This first-in-class platform combines the power of dendritic cell-based vaccines with the advantages of allogeneic stimulation of the immune system whilst bypassing the complex logistics of autologous DC vaccines. The company’s lead product DCP-001 is in Phase I/IIa in patients with Acute Myeloid Leukemia (AML). A Phase II efficacy study will start shortly. Several products for solid cancers are in preclinical development, using peptide loaded DCOne-based vaccines. From October 2012 to December 2013 (1 year 3 months) Chief Executive Officer @ I was one of the founders of the company, which I ran for 8 years before stepping out of the day-to-day management in order to concentrate on the Findacure charity and my consultancy work. From June 2001 to December 2009 (8 years 7 months) Senior Clinical Research Manager @ As the medical member of the European Project Team, I was responsible for the “hands-on” management of ongoing clinical trials and the design and implementation of new studies. I was involved in safety assessments, addressing questions from the regulatory authorities, the supervision of writing of clinical trial reports and the writing of Clinical Expert Reports. I was responsible for the conception and implementation of the clinical development plan for a combination product with the new device. From November 1999 to June 2001 (1 year 8 months) Team Member Medicine @ An international role with global responsibility for all medical aspects of the product, from the clinical development planning to the overall safety of the product. I was responsible for medical support to regulatory, including the handling of questions from the regulatory authorities. I provided medical support to Corporate Marketing during the launch phase. This included helping to develop promotional material, product monographs and training manuals, manuscripts for publication, opinion leader support, presentation of product features at advisory board meetings and internal medico-marketing meetings. I developed a creative phase IV strategy and the supervised ongoing phase IIIb trials. I was also responsible for the clinical development plan for a fixed-dose combination product. From August 1998 to October 1999 (1 year 3 months) Senior Medical Adviser @ Sole responsibility for all aspects of phase IV activities for cardiovascular products. Responsible for new strategies in phase IV development and implementation of the clinical trial programs. Conceived and set clinical trials in the areas of hypertension, angina and myocardial infarction. Took on several international roles as Medical Sub-Team member for lacidipine and international Team Member Medicine for dipyridamole. Involved in the development of opinion leader support in the areas of hypertension, myocardial infarction and stroke. Responsible for the medico-marketing input into the launch phase of a combination product, dipyridamole/aspirin, for secondary prevention of stroke. Also helped to develop pre-launch strategies with a thrombolytic for the treatment of acute ischaemic stroke. From April 1994 to August 1998 (4 years 5 months)

MB BS, Medicine @ Royal Free Hospital School of Medicine From 1986 to 1991 BSc AKC, Physiology & Pharmacology @ King's College London From 1983 to 1986 Windsor Grammar School From 1972 to 1979 Windsor CollegeWindsor College Anthony Hall is skilled in: Orphan Drugs, Rare Diseases, Clinical Trials, Clinical Development, Pharmaceutical Industry, Drug Development, Therapeutic Areas, Medicine, Protocol, CRO, GCP, CTMS, Regulatory Submissions, Medical Affairs, Biopharmaceuticals